0.82 (-%)
As of Nov 20, 2024
Source:
We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform. Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm shift in the management of cancer and that our product candidates have the potential to become cornerstones of the treatment regimens of multiple solid tumors.
Country | United States |
Headquarters | copenhagen |
Phone Number | 4570702980 |
Industry | |
CEO | Mai-Britt Zocca, Ph.D. |
Website | clinicaltrials.gov |